Sec Form 4 Filing - Dittrich Thomas J.W. @ AMGEN INC - 2012-07-31

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Dittrich Thomas J.W. 2. Issuer Name and Ticker or Trading Symbol AMGEN INC [ AMGN] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) VP, Finance & CAO (Last) (First) (Middle) ONE AMGEN CENTER DRIVE 3. Date of Earliest Transaction (MM/DD/YY) 07/31/2012 (Street) THOUSAND OAKS, CA91320 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 07/31/2012 M 25,000 A $ 69.83 38,721 D Common Stock 07/31/2012 M 3,000 A $ 42.13 41,721 D Common Stock 07/31/2012 M 2,000 A $ 50.44 43,721 D Common Stock 07/31/2012 M 2,150 A $ 58.43 45,871 D Common Stock 07/31/2012 S 32,150 D $ 82.687 ( 1 ) 13,721 ( 2 ) ( 3 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Nqso (Right to Buy) $ 69.83 07/31/2012 M 25,000 05/15/2007 05/15/2013 Common Stock 25,000 $ 0 0 D Nqso (Right to Buy) $ 42.13 07/31/2012 M 3,000 04/29/2009 04/29/2015 Common Stock 3,000 $ 0 0 D Nqso (Right to Buy) $ 50.44 07/31/2012 M 2,000 04/28/2010 04/28/2016 Common Stock 2,000 $ 0 2,000 D Nqso (Right to Buy) $ 58.43 07/31/2012 M 2,150 04/26/2011 04/26/2020 Common Stock 2,150 $ 0 4,300 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Dittrich Thomas J.W. ONE AMGEN CENTER DRIVE THOUSAND OAKS, CA91320 VP, Finance & CAO Signatures /s/ Thomas J.W. Dittrich 07/31/2012 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The price reported is an average price. The prices ranged from $82.67 to $82.75 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer. ( 2 )The shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 286 RSUs which fully vest on 4/28/2013; 615 RSUs which vest in annual installments of 307 on 4/26/2013 and 308 on 4/26/2014; 1,714 RSUs which vest in annual installments of 565, 566 and 583 on 4/25/2013, 4/25/2014 and 4/25/2015, respectively; and 1,400 RSUs which vest in two equal installments of 462 each on 4/27/2014 and 4/27/2015 and one installment of 476 on 4/27/2016. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. ( 3 )These shares include 7 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.